Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
We can see a decrease in the price for Akebia Therapeutics Inc.. Compared to yesterday it has lost -€0.016 (-1.220%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Akebia Therapeutics Inc..
With a target price of 4 € there is potential for a 209.6% increase which would mean more than doubling the current price of 1.29 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -1.220% | 3.571% | -3.563% | -23.923% | -8.696% | 117.500% | -52.791% |
| Heron Therapeutics Inc. | -0.410% | 10.879% | -0.581% | -54.196% | -30.925% | -70.630% | -94.480% |
| Evolus Inc | -0.540% | 3.399% | -16.590% | -59.326% | -33.578% | -51.733% | -63.061% |
| Sangamo Therapeutics Inc. | 1.930% | -2.426% | -34.637% | -67.260% | -37.907% | -85.570% | -97.764% |
Comments
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat